Breakthrough Diabetes Treatment Reprograms the Immune System Instead of Replacing Insulin

An engineered stem cell therapy reversed new-onset Type 1 diabetes in mice by shifting the immune system away from attacking ...
MPR

Subcutaneous Sarclisa Escena Receives FDA Nod for Multiple Myeloma

FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.

Press Release: Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector

Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector Sarclisa Escena ...

Psychedelic drug screen in mice may overlook stress and brain changes

Over the past decades, some medical researchers and neuroscientists have been exploring the possible therapeutic effects of ...

Sanofi wins FDA nod for injectable multiple myeloma therapy

Sanofi (SNY) wins FDA approval for Sarclisa Escena, a subcutaneously-delivered version of its multiple myeloma therapy ...
Fierce Pharma

Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector

Sanofi has scored FDA approval for its subcutaneous version of Sarclisa, giving the multiple myeloma treatment a potential ...
The American Journal of Managed Care

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

Approval covers all current IV isatuximab indications and introduces the first oncology product labeled for both OBI and manual SC administration. IRAKLIA (NCT05405166) established noninferiority of ...
oncnursingnews

FDA Approves Subcutaneous Isatuximab-irfc for Multiple Myeloma

FDA approves subcutaneous isatuximab-irfc for multiple myeloma indications, offering an efficient delivery alternative to intravenous administration. The US Food and Drug Administration (FDA) has ...
Targeted Oncology

FDA Approves Subcutaneous Isatuximab for Multiple Myeloma

Subcutaneous isatuximab is now approved with pomalidomide/dexamethasone, carfilzomib/dexamethasone, and bortezomib/lenalidomide/dexamethasone, aligning SC ...